Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Antonio Bertoletti

Showing results (21-30 of 224) with videos related to

Pageof 23
Sort By:
Hepatology Research : the Official Journal of the Japan Society of Hepatology|October 13, 2007
Immune response and tolerance during chronic hepatitis B virus infectionAntonio Bertoletti, Adam Gehring
Frontiers in Immunology|October 9, 2014
Age-Dependent Immune Events during HBV Infection from Birth to Adulthood: An Alternative InterpretationAntonio Bertoletti, Michelle Hong
Current Opinion in Virology|July 10, 2022
Editorial overview: Viral pathogenesisAntonio Bertoletti, Matteo Iannacone
Immunology and Cell Biology|May 22, 2023
SARS-CoV-2 clearance after breakthrough infection correlates with fit and happy T cellsMarc Veldhoen, Antonio Bertoletti
Hepatology Communications|October 9, 2019
Fine-Tuning TLR-7-Based Therapy for Functional HBV CureAntonio Bertoletti, Nina Le Bert
Seminars in Liver Disease|June 1, 2017
Clinical Trial Design for Immune-Based Therapy of Hepatitis B VirusUpkar S Gill, Antonio Bertoletti
Cellular & Molecular Immunology|April 14, 2015
Overview of the special issue on HBV immunityAntonio Bertoletti, Fu-Sheng Wang
Cellular & Molecular Immunology|September 2, 2014
The immune tolerant phase of chronic HBV infection: new perspectives on an old conceptAntonio Bertoletti, Patrick T Kennedy
Gut|May 11, 2026
CD16<sup>+</sup> γδ T cells and antibody-dependent cellular cytotoxicity: a new axis of immune control in hepatitis B virus infection?Antonio Bertoletti, Nina Le Bert
Clinical and Molecular Hepatology|June 27, 2024
Engineering HBV-specific T cells for the treatment of HBV-related HCC and HBV infection: Past, Present, and Future. Editorial on "Genetically-modified, redirected T cells target hepatitis B surface antigen-positive hepatocytes and hepatocellular carcinoma lesions in a clinical setting"Antonio Bertoletti, Anthony T Tan
Pageof 23

Showing results (21-30 of 224) with videos related to

Sort By:
Pageof 23
Hepatology Research : the Official Journal of the Japan Society of Hepatology|October 13, 2007
Immune response and tolerance during chronic hepatitis B virus infectionAntonio Bertoletti, Adam Gehring
Frontiers in Immunology|October 9, 2014
Age-Dependent Immune Events during HBV Infection from Birth to Adulthood: An Alternative InterpretationAntonio Bertoletti, Michelle Hong
Current Opinion in Virology|July 10, 2022
Editorial overview: Viral pathogenesisAntonio Bertoletti, Matteo Iannacone
Immunology and Cell Biology|May 22, 2023
SARS-CoV-2 clearance after breakthrough infection correlates with fit and happy T cellsMarc Veldhoen, Antonio Bertoletti
Hepatology Communications|October 9, 2019
Fine-Tuning TLR-7-Based Therapy for Functional HBV CureAntonio Bertoletti, Nina Le Bert
Seminars in Liver Disease|June 1, 2017
Clinical Trial Design for Immune-Based Therapy of Hepatitis B VirusUpkar S Gill, Antonio Bertoletti
Cellular & Molecular Immunology|April 14, 2015
Overview of the special issue on HBV immunityAntonio Bertoletti, Fu-Sheng Wang
Cellular & Molecular Immunology|September 2, 2014
The immune tolerant phase of chronic HBV infection: new perspectives on an old conceptAntonio Bertoletti, Patrick T Kennedy
Gut|May 11, 2026
CD16<sup>+</sup> γδ T cells and antibody-dependent cellular cytotoxicity: a new axis of immune control in hepatitis B virus infection?Antonio Bertoletti, Nina Le Bert
Clinical and Molecular Hepatology|June 27, 2024
Engineering HBV-specific T cells for the treatment of HBV-related HCC and HBV infection: Past, Present, and Future. Editorial on "Genetically-modified, redirected T cells target hepatitis B surface antigen-positive hepatocytes and hepatocellular carcinoma lesions in a clinical setting"Antonio Bertoletti, Anthony T Tan
Pageof 23